Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen, Inc. (Nasdaq: SRZN) is a biotechnology company developing Wnt pathway–modulating therapeutics with a focus on severe eye diseases, and its news flow reflects this ophthalmology and research orientation. Company press releases frequently highlight progress in its retinal disease pipeline, including updates on preclinical data for candidates such as SZN-8141, SZN-8143, and SZN-413, as well as plans related to regulatory milestones like an intended Investigational New Drug (IND) application for SZN-8141.
Investors following SRZN news can expect regular business updates tied to quarterly financial results, where Surrozen discusses research service revenue, operating expenses, and non-cash items alongside narrative commentary on pipeline momentum. These reports often describe how the company is leveraging its Wnt biology expertise and antibody technologies to advance programs in retinal vascular diseases.
Surrozen’s news stream also covers scientific and medical conference activity. The company reports presentations at ophthalmology-focused meetings such as the Association for Research in Vision and Ophthalmology (ARVO), Clinical Trials at the Summit, and various healthcare investor conferences. These announcements may include summaries of preclinical findings on Wnt-mediated retinal vascular repair and regeneration, as well as overviews of next-generation Wnt therapeutics in retinal diseases.
Corporate and governance developments are another recurring theme in SRZN news. Surrozen discloses leadership changes, including appointments to key roles like Chief Financial Officer and Vice President of Clinical Development, and reports inducement equity grants under Nasdaq Listing Rule 5635(c)(4). Updates on intellectual property, such as the issuance of U.S. patents related to its SWAP™ technology for multi-specific Wnt surrogates, and collaboration developments, including changes to related-party research agreements and details of its partnership with Boehringer Ingelheim, also appear in its announcements. For readers tracking SRZN, this news page aggregates these financial, scientific, and corporate updates in one place.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics for the Wnt pathway with emphasis on severe eye diseases, has announced its participation in the Cantor Global Healthcare Conference 2025.
The company will participate in a fireside chat on September 4, 2025, from 8:00 - 8:30 AM Eastern Time. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward at www.surrozen.com.
Surrozen (NASDAQ:SRZN), a biotechnology company focused on Wnt pathway therapeutics for eye diseases, reported Q2 2025 financial results and significant organizational developments. The company ended Q2 with $90.4 million in cash, down from $101.6 million in Q1, and posted net income of $39.7 million ($2.55 per share).
Key developments include the appointment of Dr. Daniel Chao as VP of Clinical Development, formation of a Clinical Advisory Board with leading retinal specialists, and receipt of a U.S. patent for their SWAP™ technology. The company's lead candidates, SZN-8141 and SZN-8143, continue progressing, with an IND submission for SZN-8141 planned for 2026.
Research revenue was $1.0 million, while R&D expenses increased to $6.0 million from $5.3 million year-over-year. The significant net income was primarily driven by non-cash gains from changes in fair value of tranche liability and warrant liabilities.
Surrozen (Nasdaq: SRZN), a biotechnology company focused on developing targeted therapeutics that modulate the Wnt pathway for tissue repair and regeneration, particularly in severe eye diseases, has announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.
The presentation will be available starting at 7:00 AM Eastern Time on Wednesday, August 13, 2025. Investors can access the audio webcast through Surrozen's investor relations website, with a replay available afterward.
Surrozen (NASDAQ: SRZN) has been granted U.S. Patent No. 12,297,278 for its SWAP™ technology, expanding its intellectual property portfolio in Wnt pathway therapeutics. The patent covers tetravalent, multi-specific Wnt surrogates that utilize antibody-based molecules to target key receptors in the Wnt pathway.
The company's patent portfolio now includes 6 U.S. patents, 10 international patents, and multiple pending applications. The newly granted patent specifically covers technology involving two Frizzled (Fzd) binding regions and two LRP5/6 binding regions, connected via linker moieties. Surrozen has demonstrated that multivalent binding to Fzd and LRP is crucial for maximal signaling through selective surrogate Wnt molecules.
Surrozen (SRZN) reported its Q4 and full year 2024 financial results, highlighting a strategic focus on ophthalmology pipeline programs. The company secured a two-tranche financing of $175M in gross proceeds to fund multiple ophthalmology programs through Phase 1 studies.
Key financial metrics for 2024 include:
- Cash position of $34.6M as of December 31, 2024
- Additional gross proceeds of $76.4M from March 2025 financing
- Collaboration revenue of $10M from BI milestone
- Research and development expenses decreased to $21.1M from $27.2M in 2023
- Net loss increased to $63.6M compared to $43M in 2023
The company received confirmation that Boehringer will advance SZN-413 toward clinical testing and completed a research collaboration with TCGFB for antibody development targeting TGF-β.
Surrozen (NASDAQ: SRZN) announced a strategic shift to focus on ophthalmology programs, supported by an oversubscribed $175 million private placement. The funding will advance multiple eye disease treatments through Phase 1 studies.
The company's two lead candidates for retinopathies are SZN-8141 (Fzd4/VEGF) and SZN-8143 (Fzd4/VEGF/IL-6), targeting conditions like AMD, diabetic retinopathy, and other severe eye diseases. Both compounds have shown promise in preclinical models by stimulating Wnt signaling and promoting normal retinal vessel growth while inhibiting pathological vessel development.
Surrozen will discontinue the development of SZN-043 for severe alcohol-associated hepatitis, despite its safety profile, due to insufficient early clinical benefit signals. The private placement consists of two tranches: an initial $70 million closing around March 26, 2025, and a second $105 million tranche contingent on FDA clearance of the SZN-8141 IND, expected in 2026.
Surrozen (Nasdaq: SRZN), a biotech company focused on targeted therapeutics that activate the Wnt pathway for tissue repair, has announced its participation in two major healthcare investor conferences. CEO Craig Parker will present at the Guggenheim's Inaugural Healthcare Innovation Conference on November 13, 2024, with a fireside chat at 3:00 PM ET, and at the Stifel 2024 Healthcare Conference on November 19, 2024, presenting at 2:25 PM ET. Live audio webcasts will be available through Surrozen's investor website, with recordings archived for later access.
Surrozen reported Q3 2024 financial results with significant progress in its clinical programs. The company received a $10 million milestone payment from Boehringer Ingelheim for SZN-413 development. Key highlights include substantial enrollment in the Phase 1b trial of SZN-043 for severe alcohol-associated hepatitis, with proof-of-concept data expected in H1 2025. The first cohort showed no drug-related serious adverse events and potential clinical benefits. The company reported Q3 revenue of $10 million and a net loss of $1.4 million, with cash position at $31 million as of September 30, 2024.
Surrozen (SRZN) has announced a strategic research collaboration with TCGFB to develop antibody therapeutics targeting TGF-β for treating idiopathic pulmonary fibrosis (IPF). Under the two-year agreement, Surrozen will provide antibody discovery services while TCGFB will retain all TGF-β product-related intellectual property. In compensation, TCGFB will pay Surrozen up to $6 million plus third-party costs and issue a warrant for up to 3,380,000 shares of TCGFB common stock at $0.0001 per share, subject to vesting conditions.